Get your free ETF data sample from our comprehensive offerings. Start your free trial→
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
CANC ETF · Tema Oncology ETF
The CANC Exchange Traded Fund (ETF) is provided by Tema. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 1:30 PM UTC
LIVE
CLOSED
This fund is part ofTomorrow's Treatments1M perf.+0.32%
Last price
$36.33
1M perf.
+1.48%
1M flows
+€10M
AuM
€143M
E/R
0.99%
Rating
Not rated
ESG Consensus®
CANC
$36.33
Performance & flows
Segment for quartile rank
December 11, 2025 → March 11, 2026
Create a free account to view the flows graph
CANC
$37.10
+7.25%
Tomorrow's Treatments
+3.59%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +1.48%  | +7.25% | +50.21% | N/A | N/A | -1.61% | +7.12% | +7.12%  | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
3/11/2026
$37.10
1D NAV change
-0.65%
Dividend policy
No. of holdings
56
Inception date
8/15/2023
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Investment Company
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
Tema Oncology ETF (the “Fund”) seeks to provide long-term growth
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs in your region
WDNA
1M perf.
+0.36%
E/R
0.45%
WDNA
1M perf.
-0.46%
E/R
0.45%
GNOG
1M perf.
-2.40%
E/R
0.5%
GNOM
1M perf.
-2.35%
E/R
0.5%
DOCG
1M perf.
-4.73%
E/R
0.49%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +7.25% | +50.21% | N/A | N/A |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
88.08%
Switzerland
4.56%
United Kingdom
4.33%
Japan
1.47%
Unavailable
0.62%
Other
0.94%
Sectors
Health Care
80.79%
Unavailable
19.21%
Diversification
Total weight of top 15 holdings out of 56
Top 15 holdings
Data as of January 31, 2026
REVOLUTION MEDICINES INC
BRIDGEBIO PHARMA
NOVARTIS
ASTRAZENECA
US7711951043
LILLY
BRISTOL-MYERS SQUIBB
US3723032062
Create a free account to view top holdings
MERCK & CO INC
COGENT BIOSCIENCES
NUVALENT
IMMUNOME
CELCUITY INC
AMGEN-T
JOHNSON&JOHNSON
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
Tema
Tema ID Card
Number of funds
9
Total AuM
€1.5B
Expense ratio range
0.18% - 0.99%
Average expense ratio
0.7544%
Top 5 funds by Tema
| AuM | ||
|---|---|---|
DSPY | Tema S&P 500 Historical Weight ETF Strategy | €681M |
VOLT | Tema Electrification ETF | €375M |
RSHO | Tema American Reshoring ETF | €213M |
CANC | Tema Oncology ETF | €143M |
HRTS | Tema GLP-1, Obesity & Cardiometabolic ETF | €46M |
Frequently asked questions about CANC
What does Tema Oncology ETF, CANC, invest in?
CANC is a Active ETF. This ETF provides exposure to Other Equities.
What is the Total Expense ratio (TER) of CANC?
CANC carries a total expense ratio (TER) of 0.99%, indicating the annual cost for holding the fund.
When was CANC launched?
CANC was introduced to the market on August 15, 2023. It trades on United States
Who is the ETF issuer of CANC?
Tema Oncology ETF, CANC, is provided by Tema. Learn more about Tema here.
What is the current assets under management (AUM) of CANC?
CANC oversees €143M in assets as of March 11, 2026.
How has CANC performed lately?
Based on data from March 11, 2026, CANC returned 1.48% over the past month, 7.25% over the last three months and 7.12% year-to-date.
What are the latest inflows or outflows for CANC?
As of March 11, 2026, CANC recorded net flows of +€10M over the last month and +€35M year-to-date.
Does CANC distribute dividends?
CANC follows a distributing dividend policy, meaning it pays out income to investors. As of March 11, 2026, its 12-month trailing yield was 0.05%.
What are the main country or region exposures of CANC?
As of January 31, 2026, CANC has significant geographic allocations in USA, Switzerland and United Kingdom.
In which sector or theme does CANC invest in?
As of January 31, 2026, CANC focuses largely on Health Care.
How many securities does CANC hold and how diversified is it?
As of January 31, 2026, CANC holds 56 positions in its portfolio, with 56.20% of assets concentrated in its top 15 holdings.
What are the main positions in CANC?
As of January 31, 2026, CANC top three holdings include REVOLUTION MEDICINES INC, BRIDGEBIO PHARMA and NOVARTIS.
What is the base currency of CANC?
The base currency of CANC is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
